Ascletis (1672) Announces Multiple Presentations on Obesity Pipeline at ObesityWeek® 2025

Bulletin Express

Oct 27

Ascletis Pharma Inc. (1672) reported multiple upcoming poster presentations on its small molecule and peptide obesity programs at ObesityWeek® 2025 in Atlanta, Georgia, scheduled from November 4 to 7, 2025.

Several key studies will be featured during the event. The first is a full analysis of a 28-day multiple ascending dose study of ASC30, a GLP-1 receptor biased small molecule agonist under both oral tablet and subcutaneous injection development pathways. Additional information will include once-monthly and once-quarterly formulations of ASC30. Another presentation focuses on a Phase Ib study of ASC30 as a once-monthly subcutaneous injection in participants with obesity.

Also highlighted is the combination therapy of ASC31 and ASC47. ASC31 targets both GLP-1 and GIP receptors, while ASC47 is a thyroid hormone receptor beta selective small molecule agonist designed for adipose targeting. Both candidates demonstrated notable preclinical data showing significant weight loss potential when administered together.

Ascletis Pharma Inc. noted that these investigational products are protected by patent portfolios and represent an ongoing effort to advance potential treatment options for obesity. The company cautioned that development, manufacturing, and commercialization of these products are subject to various uncertainties.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1165512402"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165512402\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165512402?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165512402","market":"hk","top_or_hot":-1,"title":"Ascletis (1672) Announces Multiple Presentations on Obesity Pipeline at ObesityWeek® 2025","media":"Bulletin Express","content":"<p>Ascletis Pharma Inc. (1672) reported multiple upcoming poster presentations on its small molecule and peptide obesity programs at ObesityWeek® 2025 in Atlanta, Georgia, scheduled from November 4 to 7, 2025.</p>\n<p>Several key studies will be featured during the event. The first is a full analysis of a 28-day multiple ascending dose study of ASC30, a GLP-1 receptor biased small molecule agonist under both oral tablet and subcutaneous injection development pathways. Additional information will include once-monthly and once-quarterly formulations of ASC30. Another presentation focuses on a Phase Ib study of ASC30 as a once-monthly subcutaneous injection in participants with obesity.</p>\n<p>Also highlighted is the combination therapy of ASC31 and ASC47. ASC31 targets both GLP-1 and GIP receptors, while ASC47 is a thyroid hormone receptor beta selective small molecule agonist designed for adipose targeting. Both candidates demonstrated notable preclinical data showing significant weight loss potential when administered together.</p>\n<p>Ascletis Pharma Inc. noted that these investigational products are protected by patent portfolios and represent an ongoing effort to advance potential treatment options for obesity. The company cautioned that development, manufacturing, and commercialization of these products are subject to various uncertainties.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis (1672) Announces Multiple Presentations on Obesity Pipeline at ObesityWeek® 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis (1672) Announces Multiple Presentations on Obesity Pipeline at ObesityWeek® 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-27 18:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascletis Pharma Inc. (1672) reported multiple upcoming poster presentations on its small molecule and peptide obesity programs at ObesityWeek® 2025 in Atlanta, Georgia, scheduled from November 4 to 7, 2025.</p>\n<p>Several key studies will be featured during the event. The first is a full analysis of a 28-day multiple ascending dose study of ASC30, a GLP-1 receptor biased small molecule agonist under both oral tablet and subcutaneous injection development pathways. Additional information will include once-monthly and once-quarterly formulations of ASC30. Another presentation focuses on a Phase Ib study of ASC30 as a once-monthly subcutaneous injection in participants with obesity.</p>\n<p>Also highlighted is the combination therapy of ASC31 and ASC47. ASC31 targets both GLP-1 and GIP receptors, while ASC47 is a thyroid hormone receptor beta selective small molecule agonist designed for adipose targeting. Both candidates demonstrated notable preclinical data showing significant weight loss potential when administered together.</p>\n<p>Ascletis Pharma Inc. noted that these investigational products are protected by patent portfolios and represent an ongoing effort to advance potential treatment options for obesity. The company cautioned that development, manufacturing, and commercialization of these products are subject to various uncertainties.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1165512402","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165512402","pubTimestamp":1761561969,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascletis Pharma Inc. (1672) reported multiple upcoming poster presentations on its small molecule and peptide obesity programs at ObesityWeek® 2025 in Atlanta, Georgia, scheduled from November 4 to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"歌礼(1672)在ObesityWeek上宣布就肥胖管道进行多场演讲®2025","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1},"content_text":"Ascletis Pharma Inc. (1672) reported multiple upcoming poster presentations on its small molecule and peptide obesity programs at ObesityWeek® 2025 in Atlanta, Georgia, scheduled from November 4 to 7, 2025.\nSeveral key studies will be featured during the event. The first is a full analysis of a 28-day multiple ascending dose study of ASC30, a GLP-1 receptor biased small molecule agonist under both oral tablet and subcutaneous injection development pathways. Additional information will include once-monthly and once-quarterly formulations of ASC30. Another presentation focuses on a Phase Ib study of ASC30 as a once-monthly subcutaneous injection in participants with obesity.\nAlso highlighted is the combination therapy of ASC31 and ASC47. ASC31 targets both GLP-1 and GIP receptors, while ASC47 is a thyroid hormone receptor beta selective small molecule agonist designed for adipose targeting. Both candidates demonstrated notable preclinical data showing significant weight loss potential when administered together.\nAscletis Pharma Inc. noted that these investigational products are protected by patent portfolios and represent an ongoing effort to advance potential treatment options for obesity. The company cautioned that development, manufacturing, and commercialization of these products are subject to various uncertainties.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}